Infectious diseases still represent one of the main causes of morbidity and mortality globally due to the phenomenon of drug resistance, highlighted by the WHO in 2019 as one of the ten threats to global health. In particular, there is a worrying increase in the frequency and spectrum of antibiotic resistance in some bacterial pathogens, with particular reference to Mycobacterium tuberculosis and several Gram-positive (e.g., Streptococcus pneumoniae, Staphylococcus aureus, and enterococci) and Gram-negative pathogens (e.g., Klebsiella pneumoniae, Escherichia coli, Enterobacter spp, Acinetobacter baumannii, and Pseudomonas aeruginosa). In recent years, the emergence of resistance to last-resort antibiotics, such as carbapenems and polymyxins, makes it urgent to develop new therapeutic approaches capable of effectively addressing the global emergency of antimicrobial resistance (AMR). The rate of AMR insurgence, in fact, widely surpasses the rate of new antimicrobials development, as in the period 2017-2021 only 13 new antibiotics have been approved. Today, about 700,000 deaths are caused every year by infectious diseases due to drug-resistant pathogens.  A number that is expected to increase, with some projections indicating around 10 million deaths per year by 2050 if appropriate countermeasures are not taken. In light of this emergency, the identification and development of new therapeutic approaches capable of effectively combating drug resistance are urgently needed, possibly through a strategy that can act both directly against the bacterial pathogen and by enhancing the immune response.